News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Targeted Intervention Necessary for Low Health-Related Quality of Life Scores in Young Survivors of Colorectal Cancer

January 16, 2021
Conor Killmurray
Article
Conference|ASCO Gastrointestinal Cancer Symposium

Data presented at the 2021 ASCO Gastrointestinal Cancers Symposium found that health-related quality of life among younger survivors of colorectal cancer is poor and social and functional well-being are also suffering as treatment durations increase.

Health-related quality of life among younger survivors of colorectal cancer is poor and social and functional well-being are also suffering as treatment durations increase, while the incidence rates increase for patients with colorectal cancer under the age of 50 years, according to data presented at the 2021 ASCO Gastrointestinal Cancers Symposium.

Using the Functional Assessment of Cancer Therapy (FACT-C) survey, which assesses health-related quality of life (HRQoL) globally, along with a cross-sectional online survey for a CRC-specific scale that looked at emotional, physical, social, and functional well-being domains, researchers evaluated the responses of 235 patients with colorectal cancer (CRC) and found an overall low score of HRQoL of 67.3 out of a possible 136 in this patient population.

The mean age of the sample was 33.76 years old and the location of the patients’ tumors were either in the colon (41.7%) or rectum (58.3%). The majority of patients (33.23%) were diagnosed with stage 2 cancer and 98% were non-metastatic, while 42% experienced relapse of their disease. One hundred and eighty-nine patients (61.4%) were 6-18 months from their diagnosis or relapse, but key demographic figures like age and ethnicity did not have a significant statistical difference between the two groups.

Patients were split into two categories of 6-18 months from their initial diagnosis or relapse, and 19-36 months from diagnosis or relapse. While researchers did not find a significant difference between the two groups in terms of emotional and physical well-being, scores were low across all domains, with social well-being the highest (15.15/28) and emotional well-being the lowest (11.44/24). Moreover, functional well-being rated close to the bottom (11.84/28), with physical well-being the second highest (15.15/28).

Higher scores for physical and emotional well-being were observed in patients who had a longer time between diagnosis compared to short-term, whereas significantly lower scores were observed in social well-being for patients who had a shorter time between their diagnosis and the survey, at 15.24/28 versus 14/28 respectively (p<0.01). This was also observed in functional well-being, which scored at 13.20 for the 6-18 month group versus 11.12 for 19-36 month group (p<0.01).

The researchers concluded that with the overall low HRQoL scores for young CRC survivors in the categories of social and functional well-being should be targeted by appropriate methods, as they were the lowest. These methods would include counseling and quality of life interventions, but further study into which of these methods would be best is needed.

Reference:

Ann Miller K, Stal J, Gallagher P et al. Health-related quality of life and time from diagnosis among young adult colorectal cancer survivors. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Abstract 34.

Related Videos
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Experts on colorectal cancer
Related Content

Fruquintinib in the FRESCO-2 Trial

September 20th 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

Presurgical FOLFOX Shows Noninferior DFS Vs Chemoradiation in Rectal Cancer

September 4th 2023

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023

Cetuximab Does Not Yield Expected Responses in BRAF+ Metastatic CRC

August 9th 2023

Trifluridine/Tipiracil Receives FDA Approval in Metastatic CRC

August 2nd 2023

Fruquintinib in the FRESCO-2 Trial

September 20th 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

Presurgical FOLFOX Shows Noninferior DFS Vs Chemoradiation in Rectal Cancer

September 4th 2023

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023

Cetuximab Does Not Yield Expected Responses in BRAF+ Metastatic CRC

August 9th 2023

Trifluridine/Tipiracil Receives FDA Approval in Metastatic CRC

August 2nd 2023

Fruquintinib in the FRESCO-2 Trial

September 20th 2023

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023

Presurgical FOLFOX Shows Noninferior DFS Vs Chemoradiation in Rectal Cancer

September 4th 2023

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023

Cetuximab Does Not Yield Expected Responses in BRAF+ Metastatic CRC

August 9th 2023

Trifluridine/Tipiracil Receives FDA Approval in Metastatic CRC

August 2nd 2023
Related Content
Advertisement

Fruquintinib in the FRESCO-2 Trial

Fruquintinib in the FRESCO-2 Trial

September 20th 2023
Article

Arvind N. Dasari, MD, and Cathy Eng, MD, gave an overview on the use of fruquintinib in colorectal cancer.


Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.

Pipeline Perspectives: Fruquintinib in Metastatic Colorectal Cancer

October 2nd 2023
Podcast

Arvind N. Dasari, MD, and Cathy Eng, MD, discuss clinical trial data that may support the FDA approval of fruquintinib in metastatic colorectal cancer, and how it may impact the standard of care.


Results from a randomized trial suggest that neoadjuvant FOLFOX may be an effective treatment for patients with locally advanced rectal cancer who are suitable to undergo sphincter-sparing surgery.

Presurgical FOLFOX Shows Noninferior DFS Vs Chemoradiation in Rectal Cancer

September 4th 2023
Article

Results from a randomized trial suggest that neoadjuvant FOLFOX may be an effective treatment for patients with locally advanced rectal cancer who are suitable to undergo sphincter-sparing surgery.


Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.


Data from the phase 2 FIRE-4.5 trial suggest that cetuximab further reinforces a bevacizumab-based chemotherapy regimen as the frontline treatment of choice for BRAF-mutant, metastatic colorectal cancer.

Cetuximab Does Not Yield Expected Responses in BRAF+ Metastatic CRC

August 9th 2023
Article

Data from the phase 2 FIRE-4.5 trial suggest that cetuximab further reinforces a bevacizumab-based chemotherapy regimen as the frontline treatment of choice for BRAF-mutant, metastatic colorectal cancer.


Results from the phase 3 SUNLIGHT trial support the approval of trifluridine/tipiracil plus bevacizumab in patients with metastatic, previously treated metastatic colorectal cancer.

Trifluridine/Tipiracil Receives FDA Approval in Metastatic CRC

August 2nd 2023
Article

Results from the phase 3 SUNLIGHT trial support the approval of trifluridine/tipiracil plus bevacizumab in patients with previously treated, metastatic colorectal cancer.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.